SAINT LAURENT, QUEBEC, Jan 25, 2010 (Marketwire via COMTEX) -- IntelGenx Corp. (IGX)(US:IGXT) ("IntelGenx") today announced a strategic alliance with LTS Lohmann Therapie-Systeme AG ("LTS") for the exclusive manufacturing of products developed by IntelGenx using its VersaFilm™ drug delivery technology. VersaFilm™ is IntelGenx's immediate release wafer technology. It is comprised of a thin polymeric film using United States Pharmacopeia (USP) components that are safe and approved by the Food and Drug Administration (FDA) for use in food, pharmaceutical and cosmetic products. VersaFilm™ provides a patent-protected method of re-formulating approved pharmaceuticals in a more convenient and discrete oral dosage form.
In announcing the deal, Dr. Horst G. Zerbe, President and Chief Executive Officer of IntelGenx, said "There are a select few companies capable of manufacturing pharmaceutical films on a global scale in GMP facilities, so we are very pleased to have entered this partnership with LTS, the worldwide leader in film manufacturing. We feel this partnership weds our pharmaceutical film development expertise with LTS's impressive manufacturing capabilities and scope, giving us the necessary tools to successfully develop novel film products from the bench through to regulatory approval. This relationship also strengthens our IP position by combining patents from both companies."
Dr. Zerbe added, "With our most advanced film product having already successfully completed a pilot bioequivalency study and now moving into pivotal studies, our plan is to have LTS begin manufacturing scale up soon."
IntelGenx currently has three products in development using the VersaFilm™ technology. They are in the process of seeking commercial and development partners for each of them.
About IntelGenx Corp.:
IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx's research and development pipeline includes products for the treatment of pain, hypertension, osteoarthritis and depressive disorders. More information is available about the company at www.intelgenx.com.
About LTS Lohmann Therapie Systeme AG:
LTS Lohmann Therapie Systeme AG, headquartered in Germany, is an independent company founded in 1984 for the purpose of developing and producing drug delivery systems. With factories in Europe and the USA, in excess of 1,000 employees, and the world's largest production capacity for transdermal therapeutic and wafer-like systems, LTS is regarded as a pioneer in the development and production of transdermal and film form oral systems.
For the past 20 years LTS has enjoyed an impressive period of growth to become one of the world's leading suppliers of transdermal and oral systems for the international pharmaceutical industry. More information is available about LTS at www.ltslohmann.com.
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K for the fiscal year ended December 31, 2008, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.
SOURCE: IntelGenx Corp.
Dr. Horst G. Zerbe
President and CEO
+1 514-331-7440 (ext. 201)
+1 514-331-0436 (FAX)